6628.HK
Price:
$1.64
Market Cap:
$586.32M
Transcenta Holding Limited, a clinical stage biopharmaceutical company, engages in the discovery, research, development, manufacture, and commercialization of various drugs in the People's Republic of China and the United States. The company develops MSB2311, a humanized PD-L1 monoclonal antibody (mAb) candidate for TMB-H solid tumors; TST001, a humanized claudin 18.2 mAb candidate for solid tumors, such as gastric cancer and is under Phase II clinical trial; TST005, a PD-L1/TGF-ß bi-functional antibody candidate which is under Phase Ia clinical trial for solid tumors, including certain lung cancers; TST010, an antibody candidate targeting regulatory T cells to enhance T cell mediated tumor ...[Read more]
Industry
Biotechnology
IPO Date
2021-09-29
Stock Exchange
HKSE
Ticker
6628.HK
According to Transcenta Holding Limited’s latest financial reports and current stock price. The company's current ROE is -35.11%. This represents a change of 293.87% compared to the average of -8.91% of the last 4 quarters.
The mean historical ROE of Transcenta Holding Limited over the last ten years is -17.78%. The current -35.11% ROE has changed 97.43% with respect to the historical average. Over the past ten years (40 quarters), 6628.HK's ROE was at its highest in in the June 2021 quarter at 51.26%. The ROE was at its lowest in in the September 2021 quarter at -18.33%.
Average
-17.78%
Median
-33.11%
Minimum
-87.28%
Maximum
52.25%
Discovering the peaks and valleys of Transcenta Holding Limited ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 63.11%
Maximum Annual ROE = 52.25%
Minimum Annual Increase = -320.63%
Minimum Annual ROE = -87.28%
Year | ROE | Change |
---|---|---|
2024 | -38.62% | -14.20% |
2023 | -45.01% | 63.11% |
2022 | -27.60% | -68.38% |
2021 | -87.28% | -320.63% |
2020 | 39.56% | -24.30% |
The current ROE of Transcenta Holding Limited (6628.HK) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-37.08%
5-year avg
-31.79%
10-year avg
-17.78%
Transcenta Holding Limited’s ROE is less than Abbisko Cayman Limited (1.38%), greater than Brii Biosciences Limited (-18.42%), greater than Shanghai HeartCare Medical Technology Corporation Limited (-1.28%), greater than Antengene Corporation Limited (-34.62%), greater than Zhaoke Ophthalmology Limited (-12.08%),
Company | ROE | Market cap |
---|---|---|
1.38% | $6.80B | |
-18.42% | $1.30B | |
-1.28% | $1.50B | |
-34.62% | $2.00B | |
-12.08% | $1.44B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Transcenta Holding Limited using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Transcenta Holding Limited or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Transcenta Holding Limited's ROE?
How is the ROE calculated for Transcenta Holding Limited (6628.HK)?
What is the highest ROE for Transcenta Holding Limited (6628.HK)?
What is the 3-year average ROE for Transcenta Holding Limited (6628.HK)?
What is the 5-year average ROE for Transcenta Holding Limited (6628.HK)?
How does the current ROE for Transcenta Holding Limited (6628.HK) compare to its historical average?